Modeling superimposed preeclampsia using Ang II (Angiotensin II) infusion in pregnant stroke-prone spontaneously hypertensive rats by Morgan, Hannah L. et al.
208
Hypertensive disorders of pregnancy range from mild gesta-tional hypertension to severe preeclampsia. Prevalence is 
increasing worldwide as many pregnant women have a higher 
chance of developing complications because of possessing risk 
factors prepregnancy, such as advanced maternal age, increased 
body mass index, obesity, and preexisting hypertension.1–4 An 
increasingly common gestational hypertensive disorder is super-
imposed preeclampsia, which is the development of preeclampsia 
superimposed on a background of preexisting chronic hyper-
tension. These conditions are multifactorial, and like human 
essential hypertension, the causes are not fully understood.5–7
Major cardiovascular adaptations are needed to sustain 
healthy pregnancy; for example, an elevated cardiac output 
(CO; ≈40% greater than nonpregnant) and increased heart 
rate (10–20 bpm higher than nonpregnant) usually associated 
with decreased blood pressure.8 This fall in blood pressure is 
a result of reduced vascular resistance and altered sensitivity 
to the renin–angiotensin system (RAS), specifically a reduced 
sensitivity to Ang II (angiotensin II).8,9 The main extrarenal 
source of the RAS is the placenta, which increases expres-
sion of all RAS components during pregnancy.10–13 However, a 
reduction in RAS component expression and hypersensitivity 
to Ang II has been observed in women with gestational hyper-
tensive disorders.12,14,15 These disorders are associated with 
increased blood pressure and systemic vascular dysfunction, 
which ultimately have a detrimental impact on the offspring.16
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Abstract—Hypertensive disorders of pregnancy are the second leading cause of maternal deaths worldwide. Superimposed 
preeclampsia is an increasingly common problem and often associated with impaired placental perfusion. Understanding 
the underlying mechanisms and developing treatment options are crucial. The pregnant stroke-prone spontaneously 
hypertensive rat has impaired uteroplacental blood flow and abnormal uterine artery remodeling. We used Ang II 
(angiotensin II) infusion in pregnant stroke-prone spontaneously hypertensive rats to mimic the increased cardiovascular 
stress associated with superimposed preeclampsia and examine the impact on the maternal cardiovascular system and 
fetal development. Continuous infusion of Ang II at 500 or 1000 ng/kg per minute was administered from gestational day 
10.5 until term. Radiotelemetry and echocardiography were used to monitor hemodynamic and cardiovascular changes, 
and urine was collected prepregnancy and throughout gestation. Uterine artery myography assessed uteroplacental 
vascular function and structure. Fetal measurements were made at gestational day 18.5, and placentas were collected 
for histological and gene expression analyses. The 1000 ng/kg per minute Ang II treatment significantly increased 
blood pressure (P<0.01), reduced cardiac output (P<0.05), and reduced diameter and increased stiffness of the uterine 
arteries (P<0.01) during pregnancy. The albumin:creatinine ratio was increased in both Ang II treatment groups (P<0.05; 
P<0.0001). The 1000 ng/kg per minute–treated fetuses were significantly smaller than vehicle treatment (P<0.001). 
Placental expression of Ang II receptors was increased in the junctional zone in 1000 ng/kg per minute Ang II–treated 
groups (P<0.05), with this zone showing depletion of glycogen content and structural abnormalities. Ang II infusion in 
pregnant stroke-prone spontaneously hypertensive rats mirrors hemodynamic, cardiac, and urinary profiles observed 
in preeclamptic women, with evidence of impaired fetal growth.  (Hypertension. 2018;72:208-218. DOI: 10.1161/
HYPERTENSIONAHA.118.10935.) • Online Data Supplement
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Ang II infusion is commonly used for generating experi-
mental models of hypertension in wild-type rodents, pro-
moting hypertrophy, fibrosis of the heart, and increased 
vasoconstriction.17–20 Although pregnancy is associated with 
reduced sensitivity to Ang II,9 manipulation of the RAS by 
increasing Ang II systemically in normotensive rodent preg-
nancy can mimic preeclamptic phenotypes, such as impair-
ment of vascular remodeling and trophoblast invasion and 
increased cardiovascular load, which subject the dams to 
the greater cardiovascular stress.16,21 In these models, Ang II 
causes an increase in blood pressure, placental inflammation, 
and fetal growth restriction (FGR).16,21,22
Pregnant stroke-prone spontaneously hypertensive 
(SHRSP) rats have constantly elevated blood pressure, com-
pared with the normotensive Wistar Kyoto (WKY) strain, and 
are hypertensive throughout pregnancy. SHRSP rats also dem-
onstrate aspects of preeclampsia, such as reduced uteropla-
cental blood flow and impaired uterine artery function in late 
pregnancy.23 These vascular changes have been found to be 
independent of preexisting hypertension and are not observed 
in WKY pregnancy. Yet, the SHRSP are still able to maintain 
pregnancy and produce viable offspring.23
In this study, we have used Ang II infusion for the first 
time in a rat model of chronic hypertension during pregnancy. 
Our aim was to generate a novel model of superimposed pre-
eclampsia for the investigation of Ang II dysregulation on 
pregnancy and fetal growth. We hypothesized that Ang II infu-
sion would imitate superimposed preeclamptic phenotypes in 
pregnant SHRSP. This would include an increased hyperten-
sive insult on the maternal cardiovascular system of the preg-
nant SHRSP, impacting the maternal cardiovascular system 
response to pregnancy and the development of the offspring.
Materials and Methods
A detailed description of methods is available in the online-only Data 
Supplement. Data supporting these findings are available from the 
corresponding author on reasonable request.
Animals
SHRSP and WKY rats, bred and maintained at the University of 
Glasgow, were housed in controlled 12-hour light/dark conditions 
with a constant temperature (21°C±3°C) with ad libitum access 
to water and standard diet (rat and mouse No.1 maintenance diet, 
Special Diet Services). All animal procedures were approved by the 
Home Office according to the Animals (Scientific Procedures) Act 
1986 (Project License 60/9021). Virgin females were time mated at 
12 weeks (±4 days) of age with stud males of the respective strain. 
Gestational day (GD) 0.5 was confirmed by presence of a copula-
tion plug. Animals were excluded at this stage if pregnancy was not 
confirmed. Pregnant SHRSP rats were randomly assigned to 1 of 3 
treatment groups (0.9% saline vehicle or Ang II at either 500 or 1000 
ng/kg per minute); numbers of rats used per treatment are detailed in 
Table S1 in the online-only Data Supplement. Pregnant WKY rats 
were used for baseline measurements only and were not assigned to 
an Ang II treatment group. Dams where blood pressure was being 
monitored by radiotelemetry were allowed to progress to parturition, 
and others were euthanized at GD18.5 for tissue collection.
Ang II Infusion
Primed Alzet 2002 minipumps were implanted at GD10.5 subcutane-
ously on the right flank of the dam under anesthesia (2% isoflurane 
in 1.5 L/min oxygen). A constant infusion of either 500 or 1000 ng/
kg per minute Ang II (Sigma) was delivered or 0.9% sterile saline as 
vehicle controls. Doses were chosen based on previous studies con-
ducted in pregnant Sprague Dawley rats.22 Minipumps operated at a 
constant rate of 5.0 µL/h (±0.75 µL/h) for 14 days or until euthanasia.
Blood Pressure Measurement
A radiotelemetry transmitter was implanted in 10-week-old SHRSP 
females, as previously described.24 Systolic and diastolic blood 
pressures, heart rate, and activity were continuously monitored 
 prepregnancy and throughout gestation and parturition using the 
Dataquest system (Data Sciences International).
Echocardiography and Uterine Artery Doppler
Echocardiography and uterine artery Doppler waveform recordings 
were performed prepregnancy, at GD6.5, GD14.5, and GD18.5. Rats 
were anaesthetized (1.5% isoflurane in 1.5 L/min oxygen), and imag-
ing of the heart and uterine artery blood flow was conducted using an 
Acuson Sequoia c256 ultrasound imager fitted with a 15-MHz linear 
array transducer. Detailed description of echocardiography and uter-
ine artery Doppler measurements and calculations can be found in 
Methods in the online-only Data Supplement.
Biochemical Urinary Analysis
Metabolic cages were used for 24-hour urine collections at GD6.5 
and GD14.5 time points. Urine was analyzed for albumin and creati-
nine concentration using Roche Cobas C311 Analyser and commer-
cially available rodent kits (Roche).
Uterine Artery Myography
Uterine arteries were dissected in calcium-free physiological salt 
solution. One- to two-mm sections from the central portion of these 
arteries were mounted on a Danish Myo Technology multiwire myo-
graph system 620 mol/L in physiological salt solution with Ca2+ with 
95% O2 and 5% CO2. These vessels were normalized and checked for 
viability as previously described.23 The contractile dose response to 
noradrenaline was assessed (1×10−8 to 1×10−5 mol/L), and relaxation 
response to carbachol and sodium nitroprusside was assessed (1×10−9 
to 2×10−5 mol/L) after pre-constriction with 2×10−5 mol/L noradrena-
line. External and internal diameters were determined over a range 
of physiological pressures (10–120 mm Hg) using a pressure myo-
graph system (Danish Myo Technology) in calcium-free physiologi-
cal salt solution. Wall thickness, cross-sectional area, wall stress, and 
wall strain were then calculated (details provided in Methods in the 
online-only Data Supplement).
Fetal Weight Distribution
Individual fetal weights at GD18.5 were recorded and pooled for each 
treatment group. Histograms of these weights were created using 
the relative percentage frequencies for each weight, and a nonlinear 
regression was then performed using a Gaussian distribution. The rela-
tive frequency distributions were used to determine which weight rep-
resented the lowest fifth percent of vehicle fetal weights (fifth centile).
Placental Gene Expression
RNA was extracted from mesometrial, junctional, and labyrinth 
zones of the placenta using the miRNeasy mini kit (Qiagen) accord-
ing to manufacturer’s instructions. cDNA templates were produced, 
and Taqman quantitative polymerase chain reaction was performed 
for components of the RAS (Ang II receptor type-1 [Agtr1], Ang 
II receptor type-2 [Agtr2], and angiotensin-converting enzyme 
2 [Ace2]), markers of oxidative stress (hypoxia-inducible factor 
1-alpha [Hif1α] and superoxide dismutase 1 [Sod1]), and inflamma-
tion (C-C chemokine receptor type 11 [Ccrl1] and C-C chemokine 
ligand 2 [Ccl2]). See Table S2 for primer sequences.
Histology
Periodic acid Schiff stain was used to assess morphological differ-
ences of the maternal kidney and placenta.23 Placental glycogen cell 
content was determined by the percentage of positive magenta stain-
ing in the junctional zone analyzed using Image J software. Placentas 
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Figure 1. Radiotelemetry data show systolic and diastolic blood pressures (A–B), activity (C), and heart rate (D). Negative gestational 
days (GDs) indicate prepregnancy; GD0.5 to GD10.5 indicates pregnancy before Ang II (angiotensin II) infusion. Ang II or vehicle infusion 
began on GD10.5 and was sustained until parturition (approximately GD22). Open arrows indicate conception; solid black arrows indicate 
minipump implantation. Area under the curve was compared using 1-way ANOVA for pre–Ang II infusion (GD0.5–GD10.5) and post–Ang II 
infusion (GD10.5–GD21.5); n=3 to 4; *P<0.05, **P<0.01 for 1000 ng/kg per minute vs vehicle; ††P<0.01 for 500 ng/kg per minute vs vehicle.
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were also scored for junctional disorganization (see online-only Data 
Supplement for scoring details).
Statistical Analysis
Coding was used to blind observers to the treatment groups during 
data acquisition/analysis and decoded before statistical analysis. All 
data are presented as mean±SEM. Telemetry data are presented as 
12-hour averages and were analyzed using area under the curve for 
pre– and post–Ang II infusion, compared using 1-way ANOVA with 
Tukey post hoc tests. Regression analysis was used to find the rate of 
change where longitudinal measurements were made from the same 
dams over gestation; these gradients were then compared with a null 
hypothesis mean of 0 using a 1-sample t test to determine gestational 
dependent change. All other comparisons of the 3 treatment groups 
were analyzed using 1-way ANOVA with a Tukey post hoc test unless 
otherwise stated. Gene expression analysis was conducted using the 
delta cycle threshold (dCT) values. A P<0.05 was deemed to repre-
sent a statistically significant result.
Results
Blood Pressure Profile During Ang II–Infused 
Pregnancy
Ang II infusion from GD10.5 caused significant increases in 
systolic and diastolic blood pressures (Figure 1A and 1B). 
The rise in systolic pressure reached significance in the 1000 
ng/kg per minute Ang II treatment group (192±2.1 versus 
144±2.3 mm Hg; P<0.05), and diastolic pressure was signifi-
cantly increased in both the 500 ng/kg per minute Ang II and 
the 1000 ng/kg per minute Ang II treatment groups (157±2.3 
and 158±2.2 versus 105±1.7 mm Hg; P<0.01, respectively) 
compared with vehicle. Dams treated with 1000 ng/kg per min-
ute Ang II were significantly less active than the vehicle group 
during the nocturnal (awake) periods (2.4±0.3 versus 3.1±0.2 
counts/min; P<0.05; Figure 1C). Mean heart rate was not sig-
nificantly affected by Ang II treatment (Figure 1D); however, 
the 1000 ng/kg per minute Ang II treatment group lost the typi-
cal amplitude in diurnal rhythm.
Cardiac and Vascular Parameters
No significant differences were observed in left ventricular 
mass, stroke volume, and CO at GD6.5 (pre–Ang II treatment; 
Figure 2). Left ventricular mass was not significantly altered 
by Ang II treatment (Figure 2A). Stroke volume in vehicle-
treated SHRSP showed a significant increase post–Ang II 
infusion (168±12 µL GD6.5 versus 214±17 µL GD18.5; 
P<0.05; Figure 2B). This change was not observed in the 500 
ng/kg per minute Ang II treatment group and was significantly 
reduced in the 1000 ng/kg per minute Ang II treatment group 
(182±17 versus 90±15 µL; P<0.05; Figure 2B). Comparison 
of the rate of change in stroke volume showed that the 1000 
ng/kg per minute Ang II group had a significantly lower 
stroke volume compared with vehicle (P<0.001) and 500 ng/
kg per minute Ang II treatment group (P<0.05). These same 
trends were observed in the CO response post–Ang II infu-
sion with vehicle-treated SHRSP demonstrating a significant 
increase in CO (63±5 mL/min GD6.5 versus 79±6 mL/min 
GD18.5; P<0.05; Figure 2C). No change was observed in the 
500 ng/kg per minute Ang II treatment group. The 1000 ng/
kg per minute Ang II treatment group demonstrated a sig-
nificant reduction in CO (73±6 mL/min GD6.5 versus 36±6 
mL/min GD18.5; P<0.05; Figure 2C). Comparison of the rate 
of change in CO showed that 1000 ng/kg per minute had a 
significantly reduced level compared with vehicle (P<0.001) 
and 500 ng/kg per minute Ang II treatment group (P<0.05). 
Representative images of echocardiography traces are shown 
in Figure S1.
The uterine artery Doppler showed no significant differ-
ences in the systolic/diastolic ratio or resistance index between 
the 3 treatment groups at each gestational age (Figure S2).
Figure 2. Echocardiography was conducted prepregnancy 
(NP), pre–Ang II (angiotensin II; gestational day [GD] 6.5), and 
post–Ang II infusion (GD14.5 and GD18.5). A, Left ventricular 
mass was normalized to tibia length and was unchanged over 
pregnancy regardless of Ang II treatment. Pregnancy increased 
stroke volume (B) and cardiac output (C) in the vehicle group (n=5) 
while had no effect on dams treated with 500 ng/kg per minute 
Ang II (n=4). Stroke volume and cardiac output were significantly 
reduced in 1000 ng/kg per minute Ang II–treated dams (n=6). One 
sample t tests compared the gradients pre–Ang II infusion (NP to 
GD6.5; ns) and post–Ang II infusion (GD6.5–GD18.5; #P<0.05). 
One-way ANOVA compared the gradient change between 
treatment groups post–Ang II infusion (***P<0.001 vehicle vs 1000 
ng/kg per minute; †P<0.05 500 vs 1000 ng/kg per minute).
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Evidence of Proteinuria and Abnormal Kidney 
Morphology
Both high- and low-dose Ang II groups had significantly 
increased albumin:creatinine ratio compared with vehicle 
control post–Ang II treatment (1.4±0.2 500 ng/kg per minute 
and 3.0±0.3 1000 ng/kg per minute versus 0.5±0.2 vehicle; 
P<0.05; P<0.0001). Dams treated with 1000 ng/kg per minute 
Ang II demonstrated a significantly greater albumin:creatinine 
ratio than 500 ng/kg per minute Ang II treatment group 
(P<0.001) and was the only treatment group to demonstrate 
a significantly increased ratio from pre–Ang II treatment 
(0.4±0.1 versus 3.0±0.3; P<0.0001; Figure 3A).
The kidneys of Ang II–treated dams demonstrated mor-
phological differences (Figure 3B). Representative images 
show the typical SHRSP glomeruli structure with clear cell 
definition within the glomeruli capillaries and visible space 
between the visceral and parietal layers of the Bowman cap-
sule. There is evidence of Bowman capsule defects in Ang 
II–treated SHRSP kidneys, with a reduction in the space 
observed between the visceral and parietal layers.
Uterine Artery Function and Structure
The vascular reactivity of GD18.5 uterine arteries was not 
significantly altered by Ang II treatment (Figure S3). The 
uterine arteries from 1000 ng/kg per minute Ang II–treated 
dams had a significantly reduced external and internal diam-
eter compared with vehicle (2866±101 versus 3535±164 area 
under the curve; P<0.05 and 2271±88 versus 2890±34 area 
under the curve; P<0.01, respectively; Figure 4A and 4B). The 
cross-sectional area of the vessels from this group was also 
significantly reduced (3.4×105±2×105 versus 5.6×105±5×105 
area under the curve; P<0.05; Figure 4C); however, there was 
no significant differences in wall thickness (Figure 4D) or 
wall stress (Figure 4E) across the range of physiological pres-
sures. Histopathology revealed no differences in wall cross-
sectional area (Figure S4). The vessel stress/strain relationship 
showed a significant decrease in both Ang II treatment groups 
(Figure 4F), with the curves shifting to the left, indicating 
increased vascular stiffness.
Fetal Impact
There were no significant differences between untreated 
WKY and SHRSP fetal weights at GD18.5 (Figure S5). 
Ang II treatment significantly reduced GD18.5 average 
fetal weights in the 1000 ng/kg per minute Ang II treatment 
group compared with both vehicle and 500 ng/kg per minute 
Ang II treatment groups (0.71±0.04g versus 1.08±0.03g and 
0.99±0.04g; P<0.0001 and P<0.01, respectively; Figure 5A). 
Figure 3. A, Urinary albumin:creatinine ratios 
(ACR) were determined from 24-h urine 
samples collected pre–Ang II (angiotensin 
II; gestational day [GD] 6.5) and post–Ang II 
infusion (GD14.5). Ang II infusion significantly 
increased ACR at both the 500 ng/kg per 
minute (n=3) and 1000 ng/kg per minute 
(n=4) doses. The vehicle-treated group (n=3) 
demonstrated no pregnancy-dependent 
change. Two-way ANOVA compared changes 
between pre–Ang II and post–Ang II infusion; 
††††P<0.0001 and between treatment 
groups; *P<0.05, ***P<0.001, ****P<0.0001. 
B, Representative images of periodic acid 
Schiff–stained kidney sections from GD18.5 
vehicle, 500 ng/kg per minute Ang II, and 1000 
ng/kg per minute Ang II–treated dams. Arrows 
indicate Bowman space that appears reduced 
between the visceral and parietal layers as Ang 
II treatment increases.
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There were no changes in the head:body weight ratio or in 
the number of pups per litter at the fetal (GD18.5) or at neo-
natal (day 2) stage (Figure 5B and 5C). Fetal weight distri-
butions show that 47.8% of 500 ng/kg per minute Ang II 
fetuses and 95.7% of 1000 ng/kg per minute Ang II fetuses 
fell below the fifth centile for fetal weight in vehicle SHRSP 
(Figure 5D).
Placental Gene Expression and Morphology
The gene expressions of Agtr1 and Agtr2 were significantly 
increased in the mesometrial triangle of 1000 ng/kg per min-
ute Ang II–treated placentas compared with vehicle (Agtr1: 
11.70±0.3 versus 13.84±0.6 dCT; P<0.05 and Agtr2: 13.16±0.4 
versus 15.37±0.5 dCT; P<0.05; Figure 6A and 6B). Agtr2 was 
also significantly increased in the junctional zone of placenta 
from 1000 ng/kg per minute Ang II–treated dams compared 
with vehicle (11.56±0.8 versus 14.80±0.9 dCT; P<0.05; 
Figure 6B). No significant differences were observed in other 
placental layers. There were no expression changes in Ace2, 
Sod1, Hif1α, Ccrl1, or Ccl2 in the different layers (Figure S6).
Placental weights were significantly reduced by 1000 
ng/kg per minute Ang II treatment compared with vehicle 
(0.16±0.009 versus 0.24±0.008 g; P<0.0001; Figure 6C). This 
reduction in placental weight was accompanied with a loss of 
Figure 4. Pressure myography assessment of the wall properties demonstrated that uterine arteries from 1000 ng/kg per min Ang II–
treated dams had a significantly reduced diameter (both internal and external; A and B) and cross-sectional area (C), with no changes 
in wall thickness (D). Ang II (angiotensin II) treatment had no significant impact in wall stress (E); however, the stress–strain relationship 
was significantly reduced in both Ang II treatment groups (F). Area under the curve compared using 1-way ANOVA; n=3 to 6; *P<0.05, 
**P<0.01 for 1000 ng/kg per minute vs vehicle; **P<0.01 for 500 ng/kg per minute vs vehicle.
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glycogen content. Periodic acid Schiff staining showed sig-
nificantly less glycogen positive cells in the junctional zone 
of the 1000 ng/kg per minute Ang II group compared with 
vehicle (4%±1.6% versus 13%±1.5%; P<0.05; Figure 6D). 
The junctional zone of the placenta also exhibited a signifi-
cant increase in disorganization score in the 1000 ng/kg per 
minute Ang II treatment group (4±0.5 versus 2±0.3; P<0.05; 
Figure 6E). Representative images of the whole-rodent pla-
centa and junctional zone at higher magnification are shown 
in Figure 6F.
Discussion
This study has shown that administration of Ang II during 
hypertensive pregnancy can significantly impact maternal car-
diovascular physiology and the growth of the fetus. We have 
demonstrated that infusion of high dose Ang II from midg-
estation in SHRSP pregnancy increases maternal blood pres-
sure, with reduced stroke volume and thus reduced CO. The 
500 ng/kg per minute Ang II dose caused a significant increase 
in blood pressure and proteinuria and lacked the significant 
increase in CO observed in vehicle-treated SHRSP rats. 
However, we did not find any significant reduction in fetal 
weight in this group compared with vehicle. The 1000 ng/kg 
per minute Ang II dose demonstrated the greatest increase in 
blood pressure and a severe impairment of CO. This impact on 
the maternal cardiovascular system was observed in parallel 
with the development of proteinuria and reduced fetal weight, 
suggesting that this high Ang II dose is analogous to more 
extreme human preeclamptic characteristics.25,26 Human pre-
eclampsia has been associated with the development of FGR, 
and offspring from preeclampsia pregnancies have been found 
to be more at risk of cardiovascular disease.16,27 Dysregulation 
of the RAS in utero has been associated with the development 
of hypertension in later life.16,27,28 Xue et al16 demonstrated that 
offspring exposed to low pressor Ang II in utero were hyper-
sensitive to Ang II–induced hypertension as adults. These 
offspring were more likely to develop cardiovascular disease 
because of differences in developmental programming com-
pared with untreated counterparts.16
Ang II treatment caused uterine artery diameter and cross-
sectional area reductions, suggesting that the pregnancy-spe-
cific outward hypertrophic remodeling of these arteries does 
not occur to the same extent as that observed in untreated 
animals.23 This is in line with the human situation, where a 
major defect in myometrial spiral artery remodeling can be 
observed in preeclampsia and FGR.29 We have previously 
shown that SHRSP demonstrate pregnancy-dependent uter-
ine artery remodeling compared with nonpregnant SHRSP; 
however, this remodeling is impaired when compared with 
WKY rats.23 It is unclear whether the SHRSP Ang II infusion 
model is preventing the outward hypertrophic remodeling or 
reversing any pregnancy-dependant changes. Measurements 
of vessel diameter at GD10.5 before Ang II infusion would 
be needed to answer this. Previously, we have demonstrated 
Figure 5. Fetal measures were made at gestational day (GD) 18.5. A, Fetal weights were significantly reduced with 1000 ng/kg per minute 
Ang II (angiotensin II) treatment compared with vehicle and 500 ng/kg per minute. B, There was no significant change in head:body weight 
ratio or (C) the number of offspring per litter at the fetal (GD18.5) or neonatal (day 2) stage. Data are presented as litter averages for each 
dam. **P<0.01, ***P<0.001; compared using 1-way ANOVA. D, The fetal growth distributions of vehicle stroke-prone spontaneously 
hypertensive (SHRSP; n=37) and both Ang II treatment groups (n=42, 500 ng/kg per minute and n=46, 1000 ng/kg per minute) indicate 
fetuses that would be clinically classed as growth restricted; vertical dotted line represents the fifth centile for SHRSP fetal weights. The 
47.8% of 500 ng/kg per minute Ang II–treated fetuses and 95.7% of 1000 ng/kg per minute Ang II–treated fetuses fall below this threshold.
D
ow
nloaded from
 http://ahajournals.org by on July 30, 2018
Morgan et al  Ang II Infusion in Hypertensive SHRSP Pregnancy  215
Figure 6. Gene expressions were investigated in the different layers of the placenta A and B, Ang II (angiotensin II) receptor type-1 and 
type-2 expression was increased in the mesometrial triangle from 1000 ng/kg per minute Ang II treatment group. Data are presented as 
relative quantity (RQ) compared with stable housekeeper (β-actin). Delta cycle threshold values analyzed using 1-way ANOVA; *P<0.05. 
C, Placental weights at gestational day (GD) 18.5 were significantly reduced in the 1000 ng/kg per minute Ang II treatment group. D, 
Periodic acid Schiff staining was significantly reduced in placenta exposed to 1000 ng/kg per minute Ang II treatment. E, Junctional zone 
disorganization was scored by a blinded operator (1=organized typical structure, with ordered distribution of cell types; 5=no order, many 
large vacuous regions with sparse and disorganized distribution of cell types). C–E, Assessed using 1-way ANOVA with Tukey post hoc 
test; *P<0.05, ****P<0.0001. F, Representative images of whole placentas (merged images) and the junctional zone at ×20 magnification 
are shown with the junctional zone outlined by dashed lines. Jx indicates junctional zone; laboratory, labyrinth zone (placental tissues); 
and Mes, mesometrial triangle (maternal tissue including decidua).
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that SHRSP have an impaired uteroplacental blood flow and 
impaired vasorelaxation responses, so it is possible that the 
observed lack of functional changes of the uterine arteries in 
the present study occur because of preexisting impairment 
that cannot be worsened by Ang II infusion.23
Circulating Ang II levels in preeclampsia are similar 
to those found in normotensive pregnancies9; however, the 
receptor sensitivity and downstream signaling processes 
are increased.9,14,30 We demonstrated that preeclampsia-like 
symptoms can be developed midpregnancy in an animal 
model using Ang II infusion from GD10.5. This is in line 
with human pregnancies where preeclampsia symptoms do 
not arise until after 20 weeks gestation.31,32 Local tissue Ang 
II production plays a crucial role in RAS maintenance during 
pregnancy, and RAS components have been found in both 
rodent and human placenta.11,33–35 However, any local con-
trol of Ang II production by the placenta may be masked 
by exogenous administration in our model. Placental specific 
increases of Ang II, achieved using transgenic crosses, have 
shown similar preeclampsia phenotypes to those observed 
in our SHRSP Ang II infusion model.21,34,36 We found evi-
dence of increased expressions of Agtr1 and Agtr2 genes 
in the mesometrial triangle from 1000 ng/kg per minute 
Ang II–treated dams. In human decidua, an increase in 
Agtr1 has been described in preeclampsia.37 Furthermore, 
an increase in Agtr1 activation via Ang II has been found 
to reduce the placental transport of system A amino acids.38 
Vaswani et al10,11 found a gestational-dependent increase in 
the gene expression of components of the RAS (eg, Ace2 
and Agtr1a) in rodent placenta. This study suggests that the 
placental RAS is dynamic throughout pregnancy and is influ-
enced by Ang II changes. Our SHRSP Ang II infusion model 
alters the RAS once the rodent placental cell lineages are 
established during the formation of the chorioallantoic pla-
centa. However, this does not result in decreased numbers of 
fetuses per litter, suggesting Ang II infusion may be causing 
placental dysfunction rather than a failure of placental devel-
opment. Other placental defects demonstrated by Ang II 
infusion in SHRSP were a reduction in placental weight, as 
well as depletion and disorganization of the junctional zone. 
Because placental dysfunction has been well established in 
its involvement with FGR in humans,39–41 it is possible that 
these placental deficiencies have a significant impact on sus-
taining the fetus and thus promote the development of FGR 
in this model.
In this study, we investigated the in vivo cardiovascular 
changes across gestation in the SHRSP. CO has been found to 
increase by up to 40% to accommodate the need for increased 
organ perfusion during human pregnancy.8 Pregnancy is 
suggested to be a stress test for the cardiovascular system, 
with preeclampsia resulting because of a failure to mount 
an appropriate response. Severe preeclampsia is associated 
with cardiovascular impairment; specifically the increase in 
CO is often reduced or absent.26 This has been associated 
with poor placental perfusion and presence of FGR.26,42,43 
It is still not known whether the cardiovascular impairment 
occurs before the placental dysfunction or whether it is the 
dysfunction that causes systemic cardiovascular stress that in 
turn makes the situation worse. However, there is increasing 
evidence that the maternal cardiovascular system’s response 
to pregnancy is a major contributor to the development of 
gestational hypertensive disorders.44 Vehicle-treated SHRSP 
demonstrated normal CO changes during pregnancy (increas-
ing by 53% from nonpregnant) whereas SHRSP treated with 
1000 ng/kg per minute Ang II demonstrated a 40% reduction 
in CO over pregnancy.
Two Ang II doses (low 500 ng/kg per minute and high 
1000 ng/kg per minute) were investigated using the mini-
pump infusion model in this study. Women with gestational 
hypertensive complications have varying degrees of sever-
ity, and previous studies in normotensive rodents have used 
doses ranging from 500 to 1000 ng/kg per minute.16,22,30 The 
method described in the current study creates a robust, eas-
ily reproducible model of preeclampsia with potential to 
vary the cardiovascular insult by modifying the Ang II dose 
administered. Pregnant women are more resistant to the 
effects of Ang II compared with nonpregnant women; yet 
those that later develop pregnancy-induced hypertension 
have been found to have increased sensitivity.9 This model 
could, therefore, be adapted to provide information about 
an extreme condition (1000 ng/kg per minute) versus mild 
(500 ng/kg/minute). Our model differs from previous Ang II 
infusion models mimicking preeclampsia symptoms because 
SHRSP rats are hypertensive before pregnancy. We suggest 
that this model represents clinically observed superimposed 
preeclampsia, where the onset of preeclampsia occurs on a 
background of preexisting hypertension and is a condition 
that is relatively less well studied compared with other preg-
nancy-induced hypertensive conditions.45 This model is novel 
because it imposes a pregnancy-dependent increase in hyper-
tension on a model with chronically elevated blood pressure. 
Considering the increasing incidence of women with cardio-
vascular risk factors becoming pregnant in Western society, 
it is plausible that these women possess a mild hypertensive 
condition which remains undiagnosed because screening 
for hypertension is not regularly conducted in women <50 
years.6,46 However, it has been suggested that women who 
experience preeclampsia may have a predisposition to cardio-
vascular and metabolic diseases, with pregnancy highlighting 
these women at risk.7
Perspectives
Ang II infusion can be used to create a superimposed pre-
eclampsia-like phenotype in pregnant SHRSP rats. This model 
could be adapted to vary the cardiovascular stress imposed 
on the mother during pregnancy and will be a useful tool for 
investigating the impact of gestational hypertension on mater-
nal cardiovascular pathophysiology, as well as the effect this 
has on offspring later in life. This model will aid investiga-
tions into preeclampsia when studied in parallel with other 
animal models and will be useful in determining underlying 
mechanisms of gestational hypertension and in the assessment 
of novel therapeutic strategies.
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What Is New?
•	The pregnant stroke-prone spontaneously hypertensive rat infused with 
angiotensin II from midgestation provides a novel model of superimposed 
preeclampsia.
What Is Relevant?
•	Superimposed preeclampsia is becoming increasingly common because 
of increased prevalence of mothers with risk factors for hypertension 
prepregnancy.
•	Development of relevant animal models is crucial for the investigation of 
disease mechanisms and development of novel treatment options.
Summary
Ang II (angiotensin II) infusion in pregnant stroke-prone spontane-
ously hypertensive rats produces preeclamptic-like phenotypes 
that mirror hemodynamic, cardiovascular, and renal pathologies 
observed in preeclamptic women. This provides an easily repro-
ducible rodent model to investigate underlying mechanisms in the 
development of preeclamptic like conditions.
Novelty and Significance
D
ow
nloaded from
 http://ahajournals.org by on July 30, 2018
